模仿SMAC的GDC-0152是一种直接的ABCB1-ATPase活性调节器和癌细胞中的BIRC5表达抑制剂
I-Li Lin1, Yu-Ting Lin2, Yung-Chieh Chang3
1Department of Radiology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 600566, Taiwan.
Toxicology and applied pharmacology
|March 7, 2024
概括
GDC-0152通过抑制癌细胞中的ABCB1流动和BIRC5表达来克服多药性耐药性. 这种候选药物显示出治疗患有ABCB1/BIRC5相关药物耐药性的患者的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 癌症中的多药性耐药性 (MDR) 通常是由ABCB1 (P-gp) 排泄和BIRC5 (Survivin) 抗亡蛋白驱动的.
- 作为DIABLO/SMAC模仿剂的GDC-0152正在对固体瘤进行研究,但其在MDR环境中的有效性尚不清楚.
研究的目的:
- 研究GDC-0152在过度表达ABCB1的多药耐药癌症中的治疗潜力.
- 阐明GDC-0152在癌细胞中的作用背后的分子机制.
主要方法:
- 在GDC-0152对ABCB1活性和BIRC5表达的影响的in silico和in vitro分析.
- 评估GDC-0152对线粒细胞衰变和细胞内ATP水平的影响.
- 在体外和体内研究评估GDC-0152与化疗剂的结合.
主要成果:
- 在亚细胞毒性度下,GDC-0152直接抑制ABCB1-ATPase活性和多药物排放.
- GDC-0152降低了BIRC5的表达,诱导了线粒,并降低了癌细胞中的ATP水平.
- GDC-0152恢复了MDR癌细胞对化疗药物的敏感性,并在体内增强了帕克利塔塞尔的疗效.
结论:
- GDC-0152显示了治疗具有ABCB1和BIRC5介导的耐药性癌症的潜力.
- 这些发现支持针对耐药癌症的GDC-0152的患者特定临床试验设计.
更多相关视频
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.2K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K